Ritesh Rathore, MD

Associate Professor, Medicine

Ritesh Rathore
401.456.2077
825 Chalkstone Avenue

Biography

Ritesh Rathore, MD is an Associate Professor of Medicine at Boston University School of Medicine. He specializes in Hematology and Medical Oncology. His clinical and research interests include gastrointestinal cancer, Immunotherapy, head/neck/thoracic cancers and cancer clinical trials. He speaks four languages proficiently: English, Hindi, Bengali and Gujarati.

Other Positions

  • Director, Hematology & Medical Oncology, Roger Williams Medical Center

Education

  • University College of Medical Sciences, MBBS

Publications

  • Published on 9/15/2020

    Mukkamalla SKR, Huynh DV, Somasundar PS, Rathore R. Adjuvant Chemotherapy and Tumor Sidedness in Stage II Colon Cancer: Analysis of the National Cancer Data Base. Front Oncol. 2020; 10:568417. PMID: 33042845.

    Read at: PubMed
  • Published on 3/16/2019

    Keating MJ, Giscombe L, Tannous T, Reddy N, Mukkamalla SKR, DeSouza A, Rathore R. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer. J Oncol Pharm Pract. 2019 Dec; 25(8):1927-1932. PMID: 30880568.

    Read at: PubMed
  • Published on 8/27/2018

    Thakur A, Rathore R, Kondadasula SV, Uberti JP, Ratanatharathorn V, Lum LG. Immune T cells can transfer and boost anti-breast cancer immunity. Oncoimmunology. 2018; 7(12):e1500672. PMID: 30524893.

    Read at: PubMed
  • Published on 11/23/2017

    Reha J, Mukkamalla SKR, Rathore R, Somasundar PS. Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: A validation study using the National Cancer Data Base. Eur J Surg Oncol. 2018 Jan; 44(1):148-156. PMID: 29198492.

    Read at: PubMed
  • Published on 6/1/2017

    Huynh D, Mukkamalla S, Rathore R. Adjuvant therapy for pancreatic cancer: An updated analysis of treatment outcomes in elderly patients using the National Cancer Database (NCDB). Ann Oncol. 2017 Jun; 28 Suppl 3:iii72-iii73. PMID: 32136001.

    Read at: PubMed
  • Published on 6/21/2016

    Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS, Cohen SI. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016 Oct; 76(14):1257-70. PMID: 27324746.

    Read at: PubMed
  • Published on 2/23/2015

    Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer. 2015; 2015:285193. PMID: 25802762.

    Read at: PubMed
  • Published on 2/16/2015

    Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res. 2015 May 15; 21(10):2305-14. PMID: 25688159.

    Read at: PubMed
  • Published on 4/1/2014

    Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, Follett N, Sio TT, Safran H. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. Am J Clin Oncol. 2014 Apr; 37(2):162-6. PMID: 23275269.

    Read at: PubMed
  • Published on 9/23/2013

    Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. Bone Marrow Transplant. 2014 Jan; 49(1):73-9. PMID: 24056738.

    Read at: PubMed

View 19 more publications: View full profile at BUMC

View all profiles